PXD040496

PXD040496 is an original dataset announced via ProteomeXchange.

Title	Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition
Description	mTOR is a central regulator of mammalian metabolism and physiology. Aberrant hyperactivation of this pathway promotes tumor growth and metastasis and drives tumor resistance to chemotherapy and cancer drugs, making mTOR an attractive cancer therapeutic target. mTOR inhibitors have been approved to treat cancer, however, the basis for drug sensitivity remains poorly understood. Here, whole exome sequencing of three chromophobe renal cell carcinoma (chRCC) patients with exceptional mTOR inhibitor sensitivity, uncovered USP9X deubiquitinase as the only mutated gene shared by the tumors. The clonal characteristics of the mutations, revealed by studying multiple patients’ primary and metastatic samples along the years, together with the low USP9X mutation rate in unselected chRCC series, reinforced a causal link between USP9X and mTOR inhibitor sensitivity. Rapamycin treatment of USP9X depleted HeLa and renal cancer 786-O cells and the pharmacological inhibition of USP9X, confirmed a crucial role of this protein in the patients’ sensitivity to mTOR inhibition. As no direct effect of USP9X in mTORC1 was detected, we performed ubiquitylome analyses that identified p62 as a direct USP9X target. Increased p62 ubiquitination and an augmented rapamycin effect upon bortezomib treatment, together with p62 and LC3 immunofluorescence assays, suggested that dysregulated autophagy in USP9X depleted cells can synergize with mTOR inhibitors. In summary, here we show that USP9X constitutes a potential novel marker of sensitivity to mTOR inhibitors in chRCC patients and represents a clinically exploitable strategy that could increase sensitivity to these drugs
HostingRepository	PRIDE
AnnounceDate	2024-10-22
AnnouncementXML	Submission_2024-10-22_05:48:14.258.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Fernando Garcia
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	ubiquitination signature tetrapeptidyl lysine
Instrument	Q Exactive

Revision	Datetime	Status	ChangeLog Entry
0	2023-02-28 03:43:22	ID requested
1	2023-06-14 05:33:52	announced
2	2023-11-14 09:00:44	announced	2023-11-14: Updated project metadata.
⏵ 3	2024-10-22 05:48:15	announced	2024-10-22: Updated project metadata.

Rold, á, n-Romero JM, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, Calsina B, Martinez-Montes A, Monteagudo M, Mellid S, Leandro-Garc, í, a LJ, Montero-Conde C, Casc, ó, n A, Roncador G, Coloma J, Robledo M, Rodriguez-Antona C, Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition. Int J Cancer, 153(6):1300-1312(2023) [pubmed]

10.1002/ijc.34575;

submitter keyword: ubiquitinase,USP9x, human, renal cancer, mTOR

Fernando Garcia
contact affiliation	Proteomics & MS Specialist Proteomics Unit, Spanish National Cancer Research Centre (CNIO) Melchor Fernández Almagro 3. E28029 MADRID, SPAIN. Phone +34 912246900 ext 3112
contact email	fgarcia@cnio.es
lab head
Fernando Garcia
contact affiliation	Fernando García Martínez, Ph.D. Proteomics Unit, Spanish National cancer Research Center, CNIO, MADRID, SPAIN
contact email	fgarcia@cnio.es
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2023/06/PXD040496

PRIDE project URI

• PRIDE
  1. PXD040496
     1. Label: PRIDE project
     2. Name: Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition